Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts

Glioblastoma multiforme (GBM) is at present an incurable disease with a 5-year survival rate of 5.5%, despite improvements in treatment modalities such as surgery, radiation therapy, chemotherapy [e.g., temozolomide (TMZ)], and targeted therapy [e.g., the antiangiogenic agent bevacizumab (BEV)]. Dif...

Full description

Bibliographic Details
Main Authors: Yossi Nishri, Maayan Vatarescu, Ishai Luz, Lior Epstein, Mirta Dumančić, Sara Del Mare, Amit Shai, Michael Schmidt, Lisa Deutsch, Robert B. Den, Itzhak Kelson, Yona Keisari, Lior Arazi, Tomer Cooks, Vered Domankevich
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
radiotheapy
alpha particle
antiangiogeic therapy
glioblasoma multiforme
alpha DaRT
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.888100/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.888100/full

Similar Items